Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Baseline PSA levels affect general health and sexual satisfaction in men with BPH treated with finasteride or placebo.

This study observed that finasteride therapy reduced PSA levels by about 40% over a year in Chinese patients with benign prostatic hyperplasia, with varying effects based on baseline PSA levels.

This study concluded that incorporating the percentage of free PSA and urinary markers improves the accuracy of determining the need for prostate biopsy.

This dissertation found that finasteride reduced prostate volume by 6.3% and total serum PSA by 10.51% in young patients over one year.

This study observed smaller reductions in PSA levels in men under 40 taking finasteride 1mg/day compared to older age groups, without changes in testosterone levels.

This study aimed to estimate the value of urine prostate specific antigen (uPSA) as a marker for benign prostatic hyperplasia (BPH) but reported no new clinical findings.

This study explored a computer simulation method for selecting emulsion compositions in dermatology, finding that the PS biocomplex can be effectively used as an emulsifier or co-emulsifier, which streamlines the development process and reduces experimental demands.

This erratum addresses the long-term effects of finasteride on prostate-specific antigen levels but reports no new research findings.

This study found that serum PSA levels and %fPSA have limited diagnostic capability in distinguishing prostate cancer, suggesting a need for new, more specific and sensitive markers.

This study modeled how differences in trial settings and protocols, such as biopsy compliance and control arm screening, can explain the varying prostate cancer mortality reductions observed in the ERSPC and PLCO trials.

Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.

In this study, significantly fewer men treated with finasteride for moderate to severe BPH symptoms experienced acute urinary retention or required subsequent BPH-related surgery compared to placebo-treated patients.

In this study, 1 mg/day finasteride lowered serum PSA concentration in men aged 40–60, suggesting that PSA adjustment recommendations for prostate cancer screening using 5 mg/day finasteride should also apply to this lower dose for hair loss treatment.

This study found that liarozole is more effective than cyproterone acetate for improving PSA response and survival in metastatic prostate cancer after first-line endocrine therapy, while maintaining quality of life.

This paper discusses risk factors and prevention strategies for acute urinary retention secondary to benign prostatic hyperplasia, emphasizing the role of PSA levels and the benefits of medications like finasteride and alpha-blockers, but reports no new clinical results.

This study found that 5‐α‐reductase inhibitors reduce the risk of being diagnosed with prostate cancer in men who undergo regular screening, but increase the risk of sexual and erectile dysfunction.

This study found no clear evidence that finasteride negatively affects erectile function, though it does cause a reduction in ejaculatory volume and has potential implications for prostate cancer risk.

This review found dutasteride to be effective, safe, and well-tolerated for treating symptomatic BPH and provides expert commentary on its use, though the relationship with high-grade prostate cancer remains unclear.

This research analyzed 72 primary scarring alopecia cases in a Barcelona hospital, finding that the majority involved women, with a lymphocytic infiltrate and subacute onset in many cases, leading to stable disease, while neutrophilic cases had more acute episodes.

This study found that early-onset baldness in African-American men is associated with an increased risk of developing prostate cancer and more aggressive tumors, with potential interactions involving age and smoking.

In this study, corn silk extract treatment improved symptoms of testosterone-induced BPH by reducing specific mRNA expression and decreasing levels of 5α-R2, DHT, and PSA.

Combining medications is more effective for treating benign prostatic syndrome symptoms.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

This review discusses the stratification and management of male patients with lower urinary tract symptoms and benign prostatic hyperplasia in primary care and reports no new clinical results.

This study found that finasteride 1 mg daily decreased 5alpha-dihydrotestosterone levels and improved hair growth in younger men with androgenetic alopecia, with higher initial hormone levels predicting better response.

This study found that metformin is inversely associated with serum PSA levels in a dose-dependent manner, suggesting further research is needed on its potential impact on prostate cancer progression.

This review found strong evidence supporting Finasteride's effectiveness in reducing symptoms and improving quality of life in patients with larger prostate volumes, earning it a grade A recommendation for clinical use.

Dutasteride reduces DHT more effectively than finasteride.

This study found that testosterone replacement therapy, especially intramuscular administration, significantly increased PSA levels compared to placebo, while a significant correlation between PSA and testosterone was observed in non-BPH patients.